Biomark Diagnostics Inc.

Equities

20B

CA09073K1084

Biotechnology & Medical Research

Delayed Deutsche Boerse AG Other stock markets 02:18:15 2024-04-30 am EDT			5-day change	1st Jan Change
0.173 ^EUR	-4.42%		-1.14%	+17.69%

Feb. 29	Biomark Diagnostics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
Feb. 28	BioMark Diagnostics Inc. Partners with Rubix LS to Advance Blood-Based Cancer Screening in Underserved Communities	CI

BioMark Diagnostics Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022

August 29, 2022 at 05:26 pm EDT

BioMark Diagnostics Inc. reported earnings results for the first quarter ended June 30, 2022. For the first quarter, the company reported sales was CAD 0.0359 million. Net loss was CAD 0.419141 million compared to CAD 0.288758 million a year ago.

Latest news about Biomark Diagnostics Inc.

Biomark Diagnostics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 29	CI
BioMark Diagnostics Inc. Partners with Rubix LS to Advance Blood-Based Cancer Screening in Underserved Communities	Feb. 28	CI
Biomark Diagnostics Inc. Appoints Theresa Peterson as Member of Advisory Team	Feb. 26	CI
Biomark Diagnostics Closes $1.9 Million Non-Brokered Private Placement	Dec. 29	MT
Biomark Diagnostics Inc. announced that it has received CAD 1.9 million in funding	Dec. 28	CI
BioMark Announces New Patent Granted in Canada For Liquid Biopsy Based Legacy Assay	Dec. 04	MT
Biomark Diagnostics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 28	CI
BioMark Diagnostics Inc. Appoints Randolph Ford to its Strategic Advisory Team	Nov. 14	CI
Biomark Diagnostics Inc. Appoints Kevin J. Cosgriff to Its Strategic Advisory Team	23-08-30	CI
Biomark Diagnostics Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-27	CI
Biomark Diagnostics Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-07-31	CI
BioMark Diagnostics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-27	CI
BioMark Diagnostics Inc. Announces Update from Ongoing Clinical Trial Using its Lung Cancer Liquid Biopsy Test as it Prepares for Commercial Launch	23-01-11	CI
BioMark Diagnostics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-24	CI
Biomark's Glioblastoma Study Published in Cancers Demonstrates Inhibiting SAT1 Sensitized Cancer Cells Towards Radiation and Chemotherapy	22-10-27	CI
BioMark Diagnostics Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-29	CI
BioMark Diagnostics Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	22-07-11	CI
BioMark Diagnostics Inc. Auditor Raises 'Going Concern' Doubt	22-07-10	CI
BioMark Diagnostics and the Icahn School of Medicine At Mount Sinai Announce Partnership to Advance Early Lung Cancer	22-06-07	CI
BioMark Diagnostics Inc. announced that it has received CAD 1.2655 million in funding	22-05-03	CI
BioMark Diagnostics Inc. Announces Update on Company Outlook for 2022	22-03-01	CI
BioMark Diagnostics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-28	CI
BioMark Diagnostics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-23	CI
Biomark Diagnostics Inc Auditor Raises 'Going Concern' Doubt	21-07-13	CI
Biomark Diagnostics Inc Reports Earnings Results for the Full Year Ended March 31, 2021	21-07-13	CI

Chart Biomark Diagnostics Inc.

Duration

Period

More charts

Company Profile

BioMark Diagnostics Inc. is a liquid biopsy company. The Company is developing a molecular diagnostics technology platform, which leverages the power of metabolomics and machine learning algorithms to bring new cancer diagnostics to market and improve cancer prognosis by allowing physicians to detect carcinomas in the pre-symptomatic stages. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. Its cancer diagnostics technology platform leverages Omics and machine learning with a focus on cancers that are hard to detect and treat. Its liquid biopsy assay detects Spermidine/spermine N-acetyltransferase 1 (SSAT1). SSAT1 is an enzyme with elevated levels in numerous cancers. It has also developed a new high powered liquid biopsy metabolic panel assay. The new metabolic assay is instrumental for early-stage diagnosis of lung cancer. The liquid biopsy metabolic panel has demonstrated clinical detections.

Sector

Biotechnology & Medical Research

Calendar

2024-07-09 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
BIOMARK DIAGNOSTICS INC.	+17.69%	17.63M
EXACT SCIENCES CORPORATION	-20.55%	10.81B
IOVANCE BIOTHERAPEUTICS, INC.	+47.97%	3.36B
GUARDANT HEALTH, INC.	-32.75%	2.22B
BGI GENOMICS CO., LTD.	-14.15%	2.16B
VERACYTE, INC.	-26.06%	1.55B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+19.85%	1.04B
SEEGENE, INC.	-2.62%	746M
CAREDX, INC	-31.67%	425M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-43.88%	405M

Bio Diagnostics & Testing